Trial · NCT03389750
A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.
NCT03389750, Phase 2, Completed, New York State Psychiatric Institute; results first posted 2023-09-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists. Trials, record NCT03389750. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03389750
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.
- NCT number
- NCT03389750
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 16 participants, actual
- Lead sponsor
- New York State Psychiatric Institute
- Conditions
- Opioid Use Disorder
- Interventions
- Intravenous Challenge Drug
- First posted
- 2018-01-04
- Last updated
- 2023-09-07
- Results first posted
- 2023-09-07
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Positive Subjective Drug Effects (i.e., Drug "Liking"). | Throughout study enrollment period (8-9 weeks) | The positive subjective effects of the most efficacious dose of the intravenous challenge drugs. These are measured using self-reported assessment by the participant in terms of drug "liking" rated on a visual analog scale of 0-100. Higher values indicate a greater drug effect. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Positive Subjective Drug Effects (i.e., Drug Liking). | Throughout study enrollment period (8-9 weeks) | The most robust self-reported drug Liking across the various dose of each IV drug (Scale: 0-100). These data are reported only for study completers (i.e., those individuals who experienced all 13 drug \& dose drug conditions). Higher values indicate a greater drug effect. | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group13
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Positive Subjective Drug Effects (i.e., Drug Liking). | IV Placebo | 52.1 | Standard Error 1.0 | units on a scale | |
| Positive Subjective Drug Effects (i.e., Drug Liking). | IV Oxymorphone 1.8 mg | 57.5 | Standard Error 2.8 | units on a scale | |
| Positive Subjective Drug Effects (i.e., Drug Liking). | IV Oxymorphone 3.2 mg | 71.8 | Standard Error 5.2 | units on a scale | |
| Positive Subjective Drug Effects (i.e., Drug Liking). | IV Oxymorphone 5.6 mg | 71.5 | Standard Error 6.1 | units on a scale | |
| Positive Subjective Drug Effects (i.e., Drug Liking). | IV Oxymorphone 10 mg | 84 | Standard Error 4.9 | units on a scale | |
| Positive Subjective Drug Effects (i.e., Drug Liking). | IV Hydromorphone 3.2 mg | 66.3 | Standard Error 3.8 | units on a scale | |
| Positive Subjective Drug Effects (i.e., Drug Liking). | IV Hydromorphone 5.6 mg | 71.3 | Standard Error 4.9 | units on a scale | |
| Positive Subjective Drug Effects (i.e., Drug Liking). | IV Hydromorphone 10 mg | 84.3 | Standard Error 4.8 | units on a scale | |
| Positive Subjective Drug Effects (i.e., Drug Liking). | IV Hydromorphone 18 mg | 79.6 | Standard Error 5.4 | units on a scale | |
| Positive Subjective Drug Effects (i.e., Drug Liking). | IV Oxycodone 10 mg | 59.5 | Standard Error 3.9 | units on a scale |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 results by groupParticipant flow7
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Intravenous Challenge Drug | 16 | |
| Overall Study | Oxycodone | Intravenous Challenge Drug | 8 | |
| Overall Study | Oxymorphone | Intravenous Challenge Drug | 8 | |
| Overall Study | Hydromorphone | Intravenous Challenge Drug | 8 | |
| Overall Study | Placebo | Intravenous Challenge Drug | 8 | |
| Overall Study | COMPLETED | Intravenous Challenge Drug | 8 | |
| Overall Study | NOT COMPLETED | Intravenous Challenge Drug | 8 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals39
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | IV Challenge Drug: Placebo 0 mg | 0 | 16 |
| Total, all-cause mortality | IV Challenge Drug: Oxymorphone 1.8 mg | 0 | 16 |
| Total, all-cause mortality | IV Challenge Drug: Oxymorphone 3.2 mg | 0 | 16 |
| Total, all-cause mortality | IV Challenge Drug: Oxymorphone 5.6 mg | 0 | 16 |
| Total, all-cause mortality | IV Challenge Drug: Oxymorphone 10 mg | 0 | 16 |
| Total, all-cause mortality | IV Challenge Drug: Hydromorphone 3.2 mg | 0 | 16 |
| Total, all-cause mortality | IV Challenge Drug: Hydromorphone 5.6 mg | 0 | 16 |
| Total, all-cause mortality | IV Challenge Drug: Hydromorphone 10 mg | 0 | 16 |
| Total, all-cause mortality | IV Challenge Drug: Hydromorphone 18 mg | 0 | 16 |
| Total, all-cause mortality | IV Challenge Drug: Oxycodone 10 mg | 0 | 16 |
1 to 10 of 39Source ClinicalTrials.gov
See all 39 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03389750
GET https://conductscience.org/api/trials/v1/NCT03389750/event-totals?page=2